Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease With Recent or Remote Events: Systematic Review and Meta-analysis

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS CJC Open Pub Date : 2024-05-01 DOI:10.1016/j.cjco.2024.01.001
Ahmad Hayek MD , Blair J. MacDonald BA PharmD , Guillaume Marquis-Gravel MD, MSc , Kevin R. Bainey MD, MSc , Samer Mansour MD , Margaret L. Ackman PharmD , Warren J. Cantor MD , Ricky D. Turgeon BSc(Pharm), PharmD
{"title":"Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease With Recent or Remote Events: Systematic Review and Meta-analysis","authors":"Ahmad Hayek MD ,&nbsp;Blair J. MacDonald BA PharmD ,&nbsp;Guillaume Marquis-Gravel MD, MSc ,&nbsp;Kevin R. Bainey MD, MSc ,&nbsp;Samer Mansour MD ,&nbsp;Margaret L. Ackman PharmD ,&nbsp;Warren J. Cantor MD ,&nbsp;Ricky D. Turgeon BSc(Pharm), PharmD","doi":"10.1016/j.cjco.2024.01.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Ongoing debate remains regarding optimal antithrombotic therapy in patients with atrial fibrillation (AF) and coronary artery disease.</p></div><div><h3>Methods</h3><p>We performed a systematic review and meta-analysis to synthesize randomized controlled trials (RCTs) comparing the following: (i) dual-pathway therapy (DPT; oral anticoagulant [OAC] plus antiplatelet) vs triple therapy (OAC and dual-antiplatelet therapy) after percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS), and (iii) OAC monotherapy vs DPT at least 1 year after PCI or ACS. Following a 2-stage process, we identified systematic reviews published between 2019 and 2022 on these 2 clinical questions, and we updated the most comprehensive search for additional RCTs published up to October 2022. Outcomes of interest were major adverse cardiovascular events (MACE), death, stent thrombosis, and major bleeding. We estimated risk ratios (RRs) and 95% confidence intervals (CIs) using a random-effects model.</p></div><div><h3>Results</h3><p>Based on 6 RCTs (n = 10,435), DPT reduced major bleeding (RR 0.62, 95% CI 0.52-0.73) and increased stent thrombosis (RR 1.55, 95% CI 1.02-2.36), vs triple therapy after PCI or medically-managed ACS, with no significant differences in MACE and death. In 2 RCTs (n = 2905), OAC monotherapy reduced major bleeding (RR 0.66, 95% CI 0.49-0.91) vs DPT in AF patients with remote PCI or ACS, with no significant differences in MACE or death.</p></div><div><h3>Conclusions</h3><p>In patients with AF and coronary artery disease, using less-aggressive antithrombotic treatment (DPT after PCI or ACS, and OAC alone after remote PCI or ACS) reduced major bleeding, with an increase in stent thrombosis with recent PCI. These results support a minimalist yet personalized antithrombotic strategy for these patients.</p></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"6 5","pages":"Pages 708-720"},"PeriodicalIF":2.5000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2589790X24000210/pdfft?md5=650af0e97f6f4e4a0c1f0377d24db216&pid=1-s2.0-S2589790X24000210-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CJC Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589790X24000210","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Ongoing debate remains regarding optimal antithrombotic therapy in patients with atrial fibrillation (AF) and coronary artery disease.

Methods

We performed a systematic review and meta-analysis to synthesize randomized controlled trials (RCTs) comparing the following: (i) dual-pathway therapy (DPT; oral anticoagulant [OAC] plus antiplatelet) vs triple therapy (OAC and dual-antiplatelet therapy) after percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS), and (iii) OAC monotherapy vs DPT at least 1 year after PCI or ACS. Following a 2-stage process, we identified systematic reviews published between 2019 and 2022 on these 2 clinical questions, and we updated the most comprehensive search for additional RCTs published up to October 2022. Outcomes of interest were major adverse cardiovascular events (MACE), death, stent thrombosis, and major bleeding. We estimated risk ratios (RRs) and 95% confidence intervals (CIs) using a random-effects model.

Results

Based on 6 RCTs (n = 10,435), DPT reduced major bleeding (RR 0.62, 95% CI 0.52-0.73) and increased stent thrombosis (RR 1.55, 95% CI 1.02-2.36), vs triple therapy after PCI or medically-managed ACS, with no significant differences in MACE and death. In 2 RCTs (n = 2905), OAC monotherapy reduced major bleeding (RR 0.66, 95% CI 0.49-0.91) vs DPT in AF patients with remote PCI or ACS, with no significant differences in MACE or death.

Conclusions

In patients with AF and coronary artery disease, using less-aggressive antithrombotic treatment (DPT after PCI or ACS, and OAC alone after remote PCI or ACS) reduced major bleeding, with an increase in stent thrombosis with recent PCI. These results support a minimalist yet personalized antithrombotic strategy for these patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心房颤动和冠心病患者近期或远期事件的抗血栓治疗:系统回顾和荟萃分析
背景关于心房颤动(AF)和冠状动脉疾病患者的最佳抗血栓治疗仍存在争论。方法我们进行了一项系统综述和荟萃分析,综合比较了以下随机对照试验(RCT):(i) 经皮冠状动脉介入治疗(PCI)或急性冠状动脉综合征(ACS)后的双途径疗法(DPT;口服抗凝剂 [OAC] 加抗血小板)与三联疗法(OAC 和双抗血小板疗法);(iii) PCI 或 ACS 至少 1 年后的 OAC 单药疗法与 DPT。经过两个阶段,我们确定了 2019 年至 2022 年期间发表的有关这两个临床问题的系统综述,并对截至 2022 年 10 月发表的其他 RCT 进行了最全面的检索更新。我们关注的结果是主要不良心血管事件(MACE)、死亡、支架血栓和大出血。结果基于6项RCT(n = 10,435),与PCI或药物治疗ACS后的三联疗法相比,DPT减少了大出血(RR 0.62,95% CI 0.52-0.73),增加了支架血栓形成(RR 1.55,95% CI 1.02-2.36),但在MACE和死亡方面无显著差异。在 2 项 RCT(n = 2905)中,对于远期 PCI 或 ACS 的房颤患者,OAC 单药与 DPT 相比可减少大出血(RR 0.66,95% CI 0.49-0.91),但在 MACE 或死亡方面无明显差异。这些结果支持对这些患者采取最小化但个性化的抗血栓策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CJC Open
CJC Open Medicine-Cardiology and Cardiovascular Medicine
CiteScore
3.30
自引率
0.00%
发文量
143
审稿时长
60 days
期刊最新文献
Cardiac Papillary Fibroelastoma and Cerebrovascular Events: A Systematic Review Late-Onset Mitral Valve Prosthesis Dehiscence With Severe Paravalvular Leak—Infectious Versus Noninfectious Etiology Dilemma: A Case Report Assessing the Safety of Early Repatriation for Stable ST-Segment Elevation Myocardial Infarction Patients After Primary Percutaneous Coronary Intervention Coronary Sinus Reducer Improves Myocardial Perfusion in a Patient With Angina, Hypertrophic Cardiomyopathy, and Coronary Microvascular Disease Fractured and Entrapped Coronary Angioplasty Balloon Successfully Managed with Rotational Atherectomy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1